NEW France Pharma Report Out Now!
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Iris Pharma is a leading contract research organization (CRO) dedicated to ophthalmology, helping clients around the world navigate every stage of the drug and medical device development process – including in vivo ocular efficacy studies, Good Laboratory Practice (GLP) preclinical studies, bioanalysis, clinical trials, and marketing surveys. Specializing in offering preclinical and clinical research services worldwide, Iris Pharma has partnered with clients to bring nearly 70 ocular drugs and medical devices to market in the past 26 years. The company offers consulting services to help clients determine the best indication for molecules and products in development. Supporting clients ranging from small start-ups to large pharmaceutical companies and from newcomers to experts in eye therapy, Iris Pharma supports clients in every step of the process, ensuring that the preclinical development program supports the intended clinical trial design and therapeutic use.
Contact
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of…
Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven…
Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive…
In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare…
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and…
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
See our Cookie Privacy Policy Here
